

THAT WHICH IS CLAIMED IS:

1. A crystalline form of Compound I



Compound I.

2. The crystalline form of claim 1, wherein Compound I is Compound I(a):



Compound I(a).

3. The crystalline form of claim 1 or 2, wherein the crystalline form is Type 8.
4. The crystalline form of claim 3, wherein the crystalline form Type 8 is characterized by an XRPD pattern measured using Cu Kα (λ = 1.5406 Å) radiation comprising peaks at 2-theta values of 9.4, 15.4 and 16.7 °2Θ ± 0.2°2Θ.
5. The crystalline form of claim 4, wherein the XRPD pattern measured using Cu Kα (λ = 1.5406 Å) radiation further comprises at least two, five, ten, fifteen or twenty additional peaks °2Θ ± 0.2°2Θ selected from the group consisting of the following peaks:

Peak Position in °2θ	**Peak Position in °2θ**
3.1	20.7
3.5	21.4
4.8	22.1

5.6	23.3
6.1	23.6
9.7	24.2
10.7	25.1
10.8	25.6
11.2	25.9
12.7	26.6
13.2	27.1
13.6	27.5
14.2	27.9
14.4	28.4
15.7	28.6
16.5	29.2
16.9	29.7
17.6	30.9
18.3	31.4
18.5	32.1
19.0	32.5
19.1	32.8
19.8	33.4
20.3	

6. The crystalline form of any one of claims 3 to 5, wherein Type 8 is characterized by an XRPD pattern measured using Cu Kα (1.5406 Å) radiation substantially the same as shown in FIG. 29.
7. The crystalline form of any one of claims 3 to 6, wherein the crystalline form is anhydrous.
8. The crystalline form of claim 7 wherein the crystalline form comprises less than 2% by weight of water.
9. The crystalline form of any one of claims 3 to 8, wherein the crystalline form Type 8 is characterized by a DSC thermogram comprising an endothermic event with an onset temperature of 212 °C ± 2°C.
10. The crystalline form of claim 9, wherein the DSC thermogram comprises no thermal events between 50 and 100 °C and an endothermic event with an onset temperature of 212 °C ± 2°C.

11. The crystalline form of any one of claims 3 to 10, wherein the crystalline form Type 8 is characterized by a DSC thermogram substantially the same as the DSC thermogram depicted in FIG. 30
12. The crystalline form of any one of claims 3 to 11, wherein the crystalline form is substantially pure.
13. The crystalline form of claim 1 or 2, wherein the form is Type 1.
14. The crystalline form of claim 13, characterized by the XRPD pattern of FIG. 24.
15. The crystalline form of claim 13 or 14, characterized by an XRPD having at least one of the following 2Θ peaks:

peak	2Theta (degree)
1	7.34
2	12.17
3	16.43
4	17.4
5	17.65
6	18.11
7	19.37
8	19.87

16. The crystalline form of claim 15, characterized by at least two, at least three, at least four, at least five, at least six, or at least seven of the 2Θ peaks.
17. The crystalline form of claim 16, characterized by the eight 2Θ peaks.
18. The crystalline form of claim 13, wherein the crystalline form Type 1 is characterized by an XRPD pattern measured using Cu Kα (1.5406 Å) radiation comprising peaks at 2-theta values of 12.2, 19.4 and 19.9 °2θ ± 0.2°2θ.
19. The crystalline form of claim 18, wherein the XRPD pattern further comprises at least one or two specific peaks selected from the peaks at 2-theta values of 16.4 and 17.6 °2θ ± 0.2°2θ.
20. The crystalline form of claim 18, wherein the XRPD pattern further comprises at least at least two, five, ten, fifteen or twenty additional peaks in °2θ ± 0.2°2θ selected from the group:

Peak Position in °2θ	**Peak Position in °2θ**
4.2	24.1
5.0	24.3
5.8	25.0

6.1	26.2
7.3	26.5
10.7	26.8
11.2	27.5
12.9	28.1
13.5	28.5
14.0	29.5
14.9	30.2
15.4	31.0
16.4	32.2
17.0	33.1
17.4	33.5
17.7	34.2
18.1	34.4
20.7	34.9
20.9	35.6
21.4	36.2
21.7	36.9
21.9	37.3
22.9	37.8
23.4	

21. The crystalline form of any one of claims 13 to 20, wherein the crystalline form Type 1 is characterized by an XRPD pattern measured using Cu Kα (1.5406 Å) radiation substantially the same as shown in FIG. 24.
22. The crystalline form of any one of claims 13 to 21, wherein the crystalline form Type 1 is anhydrous.
23. The crystalline form of any one of claims 13 to 22, wherein the crystalline form comprises less than 2% by weight of water.
24. The crystalline form of any one of claims 13 to 23, wherein the crystalline form Type 1 is characterized by a DSC thermogram comprising an endothermic event with an onset temperature of 210 °C ± 2°C.
25. The crystalline form of claim 24, wherein the DSC thermogram comprises no thermal events between 50 and 100 °C and an endothermic event with an onset temperature of 210 °C ± 2°C.

26. The crystalline form of any one of claims 13 to 25, wherein the crystalline form Type 1 is characterized by a DSC thermogram substantially the same as the DSC thermogram depicted in FIG. 2B.
27. The crystalline form of any one of claims 13 to 26, wherein the Type 1 is at least one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% free of other forms.
28. The crystalline form of any one of claims 13 to 27, wherein the Type 1 is free from other forms.
29. The crystalline form of any one of claims 1 to 28, wherein the compound is stereochemically pure.
30. A pharmaceutical composition comprising a crystalline form according to any one of claims 1 to 29 and a pharmaceutically acceptable carrier, diluent or excipient.
31. The crystalline form according to any one of claims 1 to 29 or the pharmaceutical composition according to claim 30 for use in the treatment of HBV infection.
32. Use of the crystalline form according to any one of claims 1 to 29 in the manufacture of a medicament for treating HBV infection.